00/12/09 更新
HATORI CLINIC
1133-15,kashimada,saiwaiku,kawasaki TEL&FAX 044-522-0033
Decreased Prevalence of Alzheimer Disease
Associated With 3-Hydroxy-3-Methyglutaryl Coenzyme A Reductase Inhibitors
Benjamin
Wolozin, MD, PhD; Wendy Kellman; Paul Ruosseau, MD; Gastone G. Celesia,
MD; George Siegel, MD
Context Increasing evidence suggests
that cholesterol plays a role in the pathophysiology of Alzheimer disease
(AD). For instance, an elevated serum cholesterol level has been shown
to be a risk factor for AD.
Objective To determine whether patients
taking 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins),
which are a group of medicines that inhibit the synthesis of cholesterol,
have a lower prevalence of probable AD.
Design The experiment uses a cross-sectional
analysis comparing the prevalence of probable AD in 3 groups of patients
from hospital records: the entire population, patients receiving 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitors (hereafter referred to as the statins),
and patients receiving medications used to treat hypertension or cardiovascular
disease.
Patients The subjects studied were
those included in the computer databases of 3 different hospitals for
the years October 1, 1996, through August 31, 1998.Main Outcome Measures Diagnosis
of probable AD.Results We find that the prevalence of
probable AD in the cohort taking statins during the study interval is
60% to 73% (P<.001) lower than the total patient population
or compared with patients taking other medications typically used in the
treatment of hypertension or cardiovascular disease.Conclusions There
is a lower prevalence of diagnosed probable AD in patients taking 2 different
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitorslovastatin
and pravastatin. While one cannot infer causative mechanisms based on
these data, this study reveals an interesting association in the data,
which warrants further study.
Arch Neurol.
2000;57:1439-1443
(医)はとりクリニック
高コレステロールの治療薬・スタチン系薬剤
(メバロチン、リポバス、ローコール、セルタ、リピトールなど)にアルツハイマー病予防の可能性あり
|
3-ヒドロキシ-3-メチルグルタリルCoA還元酵素阻害薬、いわゆるスタチン系薬剤に、アルツハイマー病を予防する可能性があるようだ。米国のBenjamin
Wolozin氏らが、6万人強の心血管疾患入院患者を追跡調査し明らかにした。 調査の結果、スタチン系薬剤を服薬していた患者のアルツハイマー病発症率は、患者全体、または他の心血管疾患治療薬を服用していた患者に比べ、最大約6割(P<0.001)にとどまったという。 これまでの研究で、血清コレステロール値が高いことは、アルツハイマー病の危険因子である可能性が示唆されている。今回の研究結果は、コレステロールがアルツハイマー病の発症に関与する可能性を示す、もう一つの証拠と言えそうだ。